Carprieve Tablets (was Norocarp) 50mg 100 pack

Target species Dogs Indications for use, specifying the target species For analgesia and reduction of chronic inflammation, for example in degenerative joint disease, in dogs. Carprieve Tablets can also be used in the management of post-operative pain. Contraindications The use of Carprieve Tablets is contraindicated in the cat, and the inadvertent administration of oral carprofen tablets may induce life-threatening conditions in this species. Do not exceed the stated dose. Do not administer NSAIDs concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects. Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product. Special Warnings for each target species Use in dogs less than 6 weeks of age, or in aged animals, may involve additional risk. If such use cannot be avoided, such dogs may require a reduced dosage and careful clinical management. Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity. NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated. Special precautions for use Special precautions for use in animals None. Special precautions to be taken by the person administering the veterinary medicinal product to animals None. Adverse reactions (frequency and seriousness) None. Use during pregnancy, lactation or lay In the absence of any specific studies in pregnant bitches such use is not indicated. Interaction with other medicinal products and other forms of interaction Do not administer NSAIDs concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects. Concurrent administration of potential nephrotoxic drugs should be avoided.